Iterum Therapeutics plc
ITRMF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ITRMF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ITRMF
Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing and commercializing sulopenem, a novel oral and IV antibiotic, for the treatment of multidrug-resistant infections, with its first approved product ORLYNVAH for uncomplicated urinary tract infections.
Key risk: Going concern uncertainty
BioSniper Score
Based on 5 of 6 signals
Market Cap
$532
Cash Runway
4.8 moLead Asset
orlynvah (Approved)Next Catalyst
Patent_Expiry · Dec 23, 2039Financial data as of Sep 30, 2025.
Tracking 2 pipeline candidates · 2 clinical trials · 1 catalyst · 1 FDA decision for Iterum Therapeutics plc.
Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing and commercializing sulopenem, a novel oral and IV antibiotic, for the treatment of multidrug-resistant infections, with its first approved product ORLYNVAH for uncomplicated urinary tract infections.
- Iterum received FDA approval for ORLYNVAH (oral sulopenem) for the treatment of uncomplicated urinary tract infections in adult women with limited or no alternative oral antibacterial treatment options [sec_mda · as of 2025-11-14].
- The company is focusing on the commercial launch of ORLYNVAH in the U.S. with commercialization partner EVERSANA, expected by the end of August 2025 [sec_mda · as of 2025-08-05].
- As of September 30, 2025, Iterum had cash and cash equivalents of $11.0M, total revenue of $0.4M, and a net loss of $9.0M for the quarter [sec].
- The company has an accumulated deficit of $497.5 million as of June 30, 2025, and has expressed substantial doubt about its ability to continue as a going concern [sec_mda · as of 2025-08-05][sec_mda · as of 2025-11-14].
- Iterum is actively seeking additional capital to fund operations, commercialization, and further development of its sulopenem program [sec_mda · as of 2025-11-14].
What works
- Iterum has an FDA-approved product, ORLYNVAH, addressing an unmet need in uncomplicated urinary tract infections with limited alternative oral antibiotics [sec_mda · as of 2025-11-14].
- The company has established a commercialization partnership with EVERSANA to support the U.S. launch of ORLYNVAH [sec_mda · as of 2025-08-05].
- Iterum's sulopenem program has potential for additional indications and further clinical development [sec_mda · as of 2025-11-14].
What to weigh
- Iterum has an accumulated deficit of $497.5 million and has raised substantial doubt about its ability to continue as a going concern [sec_mda · as of 2025-08-05][sec_mda · as of 2025-11-14].
- The company has limited cash ($11.0M as of September 30, 2025) and requires additional funding to support commercialization and operations [sec][sec_mda · as of 2025-11-14].
- Iterum's strategic process to sell or license sulopenem did not result in an acceptable transaction, and future revenue from ORLYNVAH is uncertain [sec_mda · as of 2025-08-05].
- The company faces significant ongoing expenses for commercialization, manufacturing, and clinical development with no guarantee of generating sufficient revenue [sec_mda · as of 2025-11-14].
From the filings
Quoted directly from source documents.
Iterum has an FDA-approved product ORLYNVAH for uncomplicated urinary tract infections.
“ORLYNVAH™ for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options”
SEC MD&A · November 14, 2025
Iterum has substantial doubt about its ability to continue as a going concern.
“We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.”
SEC MD&A · November 14, 2025
Iterum had an accumulated deficit of $497.5 million as of June 30, 2025.
“As of June 30, 2025, we had an accumulated deficit of $497.5 million.”
SEC MD&A · August 5, 2025
Iterum expects commercial launch of ORLYNVAH by end of August 2025 with EVERSANA.
“we are focusing the majority of our efforts and resources in preparing for the commercial launch of ORLYNVAH™ in the U.S. with our commercialization partner, EVERSANA, which we expect to occur by the end of August 2025.”
SEC MD&A · August 5, 2025
Catalyst timeline
- 2039-12-23 · Patent_Expiry · ORLYNVAH — The patent/exclusivity expiry for ORLYNVAH is scheduled for 2039-12-23, which may affect long-term market exclusivity.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Iterum has substantial doubt about its ability to continue as a going concern due to cash constraints and accumulated losses [sec_mda · as of 2025-11-14].
- Need for additional capital — The company requires additional funding to support commercialization and development; cash of $11.0M as of 2025-09-30 may not sustain operations [sec][sec_mda · as of 2025-11-14].
- Commercial launch risk — ORLYNVAH launch depends on successful commercialization with EVERSANA and uncertain revenue generation [sec_mda · as of 2025-08-05].
- No strategic transaction — The process to sell or license sulopenem did not result in an acceptable transaction, limiting strategic options [sec_mda · as of 2025-08-05].
What to watch
- Commercial launch progress of ORLYNVAH in the U.S. with EVERSANA, expected by end of August 2025 [sec_mda · as of 2025-08-05].
- Iterum's ability to secure additional financing to fund operations and commercialization [sec_mda · as of 2025-11-14].
- Revenue generation from ORLYNVAH sales and its impact on cash runway [sec_mda · as of 2025-11-14].
- Any updates on business development discussions regarding sulopenem or other strategic alternatives [sec_mda · as of 2025-08-05].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Iterum Therapeutics plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Iterum Therapeutics plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
4.8 months
OCF -$7M · Net income -$9M
Lead: Approved
2 candidates
1 upcoming, next in ~4863d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 21, 2026- % of float
- 5.8%
- Days to cover
- 2.4
- Shares short
- 3,065,983
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ITRMF short interestGovernance
Frequently asked questions
What is the AI investment thesis for Iterum Therapeutics plc?
Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing and commercializing sulopenem, a novel oral and IV antibiotic, for the treatment of multidrug-resistant infections, with its first approved product ORLYNVAH for uncomplicated urinary tract infections.
What is Iterum Therapeutics plc's lead drug candidate?
Iterum Therapeutics plc's most advanced tracked candidate is orlynvah (Approved) for uncomplicated urinary tract infections (uUTI) in adult women caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options.
What is Iterum Therapeutics plc's next catalyst?
Iterum Therapeutics plc's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ORLYNVAH" — expected December 23, 2039.
Who is the CEO of Iterum Therapeutics plc?
Mr. Corey N. Fishman is the chief executive officer of Iterum Therapeutics plc (ITRMF).
Where is Iterum Therapeutics plc headquartered?
Iterum Therapeutics plc (ITRMF) is headquartered in Dublin, Ireland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.